Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem Cells

11 May 2018

Abstract excerpt

Glioblastoma (GBM) is the most aggressive primary brain cancer with an average survival time after diagnosis of only 12-14 months, with few (<5%) long-term survivors. A growing body of work suggests that GBMs contain a small population of glioma stem cells (GSCs) that are thought to be major contributors to treatment resistance and disease relapse. Identifying compounds that modulate GSC proliferation would...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Glioma Diagnosis and Treatment
Share to Neurogenesis and neuroplasticity mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29750582
DOI: 10.1177/2472555218775055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem CellsPMID 29750582Read ↗

A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem CellsSemantic proximity Read ↗

Nanomedicines Targeting Glioma Stem CellsSemantic proximity Read ↗

Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic ScreensSemantic proximity Read ↗

A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell modelsSemantic proximity Read ↗

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastomaSemantic proximity Read ↗

Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastomaSemantic proximity Read ↗

A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem CellsSemantic proximity Read ↗

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read ↗

Patient-derived glioblastoma stem cells respond differentially to targeted therapiesSemantic proximity Read ↗

Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patientsSemantic proximity Read ↗

Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assaySemantic proximity Read ↗

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.